The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Recent clinical trials have shown that agonists of muscarinic acetylcholinergic receptors can improve both psychotic and ... Antipsychotics are also associated with serious side-effects spanning ...